180 related articles for article (PubMed ID: 36746305)
1. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).
Gnanasakthy A; Levy C; Norcross L; Doward L; Winnette R
Value Health; 2023 Jun; 26(6):893-901. PubMed ID: 36746305
[TBL] [Abstract][Full Text] [Related]
2. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcome claims in European and United States orphan drug approvals.
Jarosławski S; Auquier P; Borissov B; Dussart C; Toumi M
J Mark Access Health Policy; 2018; 6(1):1542920. PubMed ID: 30425804
[No Abstract] [Full Text] [Related]
4. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.
Teixeira MM; Borges FC; Ferreira PS; Rocha J; Sepodes B; Torre C
Front Med (Lausanne); 2022; 9():968272. PubMed ID: 36035431
[TBL] [Abstract][Full Text] [Related]
5. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
[No Abstract] [Full Text] [Related]
6. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.
Cella D; Chen CI; Quek RGW; Uribarren A; Reaney M; Mastey V; Collyar D; Chassany O
Front Pharmacol; 2022; 13():1031992. PubMed ID: 36339622
[No Abstract] [Full Text] [Related]
8. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
9. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
10. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
11. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
[TBL] [Abstract][Full Text] [Related]
13. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
14. Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals.
Pinto CA; Balantac Z; Mt-Isa S; Liu X; Bracco OL; Clarke H; Tervonen T
Drug Discov Today; 2023 Oct; 28(10):103719. PubMed ID: 37467877
[TBL] [Abstract][Full Text] [Related]
15. A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility.
Gnanasakthy A; Norcross L; DeMuro Romano C; Carson RT
Value Health; 2022 Apr; 25(4):647-655. PubMed ID: 35365309
[TBL] [Abstract][Full Text] [Related]
16. International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies.
Kyte D; Reeve BB; Efficace F; Haywood K; Mercieca-Bebber R; King MT; Norquist JM; Lenderking WR; Snyder C; Ring L; Velikova G; Calvert M
Qual Life Res; 2016 Feb; 25(2):359-362. PubMed ID: 26275979
[TBL] [Abstract][Full Text] [Related]
17. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
18. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
20. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
Leo CP; Hentschel B; Szucs TD; Leo C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
